However, we found that this mechanism is unlikely to have a role in PC3 prostate cancer cells, as they express low levels of ErbB2 and the treatment with the kinase inhibitor lapatinib didn’t seem to interfere with Sema3E/PlexinD1-mediated effects (M.R., unpublished results). The gene discussed is ERBB2; the disease is Familial prostate cancer.